By studying how opioids reduce myocardial injury and how the pathways of nociception and cardioprotection are linked, the Gross Lab is designing next generation analgesics that are safe to use for those with cardiovascular disease.

Dr. Ruijiang Li's lab is focused on the development and application of novel machine learning and deep learning approaches for medical imaging analysis and precision oncology. This can lead to discovery of imaging-based biomarkers for several clinical applications including cancer detection and diagnosis, treatment response and prognosis prediction, which have the potential to transform cancer care.

Current research directions in the Liphardt lab include studies of the mechanobiology of tumor progression, super-resolution imaging of protein clustering in membranes, and single-molecule measurements of transport through biological pores and channels.

Dr. Qi's lab is currently applying genome engineering and CRISPR technologies for the interrogation of genetic interaction networks related to cell differentiation, proliferation, epigenetic regulation and diseases.

The Curtis laboratory is focused on the development and application of innovative experimental, computational, and analytical approaches to improve the diagnosis, treatment, and early detection of cancer.

The goal of Dr. Bhatt's research program is to understand the interplay between human genetics and the microbial environment in patients with hematological malignancies.

Dr. Wall's lab is developing novel approaches in systems biology to decipher the molecular pathology of autism spectrum disorder and related neurological disorders.

Dr. Gephart's lab focuses on translational neuro-oncology research, combining basic neuroscience, genetics, and tumor biology, with an unique insight into the pressing clinical questions facing patients with brain tumors.

Dr. Wang's clinical focuses are interventional radiology and diagnostic radiology.

To elucidate the function of CD72, a B lymphocyte surface protein expressed from early stages of B cell development through to the mature B cell stage, Dr. Parnes's group has used gene targeting to generate homozygous mutant mice that totally lack CD72 expression.